The U.K.-based consultancy firm Assero and the European CRO S-Cubed have joined forces to establish A3 Informatics, a joint venture that is designed to help companies working with CDISC (Clinical Data Interchange Standards Consortium) standards and assist with data management. The plan is to showcase the business at the PhUSE Annual Conference in Edinburgh, Scotland on October 8, 2017.
“I am proud to be bringing a set of technologies to the industry that it has long needed,” noted Dave Iberson-Hurst, who has advocated the use of standards for the last 15 years and has helped design and develop A3 Informatics’ “Tools: The Glandon Suite.” “I am looking forward to introducing A3 Informatics to the wider community and changing the way that we work with data.”
Iberson-Hurst has worked with S-Cubed’s managing director Scott McGregor and partner Niels Both for more than a decade. S-cubed is a European company based in Denmark and the U.K. with full-service CRO capabilities, specializing in biometrics, CDISC standards (implementation and conversion), regulatory affairs, business intelligence, quality assurance, and project management.
Both’s experience of working with CDISC standards and awareness of the issues that companies faced with implementation will be vital for A3 Informatics, according to a joint statement from both companies.
“Dave and I have worked together for many years and it is clear that there has to be another way of working with the data in clinical trials,” he said. “A3 Informatics offers solutions that can drive the industry away from endless mapping and conversions and lead to a more efficient and accurate way of working.”
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.